Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Eucalyptol→

Eucalyptol Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
470-82-6
Molecular formula
C10H18O
Molecular weight
154.2493 g/mol
Drug class
1,8-Cineolemonoterpene oxide with mucolytic and anti-inflammatory properties
Mechanism of action
Modulates airway mucus secretion and may suppress inflammatory mediator production in respiratory mucosa. The relative contribution of mucolytic, secretolytic and anti-inflammatory actions depends on dose and formulation.
Indications / reported uses
  • Symptomatic relief of cough and mucus-related symptoms in selected respiratory conditions using authorised oral or inhaled products; evidence and approved indications vary by jurisdiction

Sources: NLM MeSH — Eucalyptol (1,8-cineole) · PubMed — 1,8-Cineole respiratory pharmacology · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Eucalyptol Environmental Risk Assessment (ERA) (the Eucalyptol ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.